GO:0034377 plasma lipoprotein particle assembly: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034377 plasma lipoprotein particle assembly describes the non-covalent aggregation and arrangement of proteins and lipids to form plasma lipoprotein particles, as defined by QuickGO.
• The process is essential for transporting hydrophobic lipids through the aqueous bloodstream and is central to lipid homeostasis.
• Apolipoprotein B (APOB) is the structural backbone for VLDL, IDL, LDL, and Lp(a), while APOA1 is the backbone for HDL.
• VLDL assembly requires a complex interplay of proteins including MTTP, SAR1B, and COPII components, and is regulated by intracellular factors such as tPA-PAI-1 interaction.
• Dysregulation of lipoprotein assembly contributes to diabetic dyslipidaemia, cardiovascular disease, and Alzheimer's disease pathology.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of genes involved in lipoprotein assembly.
Description
Plasma lipoprotein particle assembly (GO:0034377) is the biological process by which proteins and lipids non-covalently aggregate and arrange into soluble lipoprotein particles that transport lipids in the bloodstream. This process is fundamental to systemic lipid homeostasis, as it allows otherwise insoluble triglycerides and cholesterol to be carried through the aqueous plasma environment. The assembly of very-low-density lipoprotein (VLDL) in the liver and chylomicrons in the intestine requires the coordinated action of apolipoproteins, lipid transfer proteins, and intracellular trafficking machinery. Researchers study GO:0034377 because defects in lipoprotein assembly underlie common metabolic disorders, including diabetic dyslipidaemia, familial hypercholesterolaemia, and elevated lipoprotein(a). The assembly process is also implicated in neurological conditions such as Alzheimer's disease, where apolipoprotein E isoforms influence lipid transport and amyloid-beta metabolism. Understanding the molecular players and regulatory checkpoints of lipoprotein assembly is therefore critical for developing targeted therapeutics. Recent advances in CRISPR gene editing have made it possible to systematically interrogate the genes controlling lipoprotein assembly, from structural apolipoproteins to auxiliary factors like MTTP and SAR1B. This article provides a research-grade overview of GO:0034377, covering its definition, mechanism, key genes, disease links, and experimental models for functional studies.
plasma lipoprotein particle assembly At A Glance
| GO ID | GO:0034377 |
|---|---|
| GO term | plasma lipoprotein particle assembly |
| Ontology | biological_process |
| Synonym | none |
| Major function | Non-covalent aggregation and arrangement of proteins and lipids to form plasma lipoprotein particles |
| Cellular location | Endoplasmic reticulum lumen and Golgi apparatus (for VLDL assembly) |
| Key structural proteins | APOB, APOA1, APOE |
| Key auxiliary factors | MTTP, SAR1B, COPII components, tPA-PAI-1 complex |
| Associated diseases | Diabetic dyslipidaemia, cardiovascular disease, Alzheimer's disease |
What Is GO:0034377?
According to the Gene Ontology, GO:0034377 plasma lipoprotein particle assembly is defined as the non-covalent aggregation and arrangement of proteins and lipids to form a plasma lipoprotein particle. In simpler terms, it is the cellular process that builds the molecular carriers responsible for moving fats and cholesterol through the blood. This process does not involve covalent bonding; instead, it relies on hydrophobic and electrostatic interactions that organize apolipoproteins and lipids into stable, soluble particles.
Why Is plasma lipoprotein particle assembly Important in Cell Biology?
GO:0034377 is critically important because plasma lipoprotein particles are the sole vehicles for transporting hydrophobic lipids in the bloodstream, and their assembly determines circulating lipid levels. Dysregulation of this process leads to pathological lipid profiles, including elevated LDL cholesterol, high triglycerides, and elevated lipoprotein(a), all of which are major risk factors for atherosclerosis and cardiovascular disease. Moreover, apolipoproteins such as APOE participate in neurobiology and are linked to Alzheimer's disease, expanding the relevance of lipoprotein assembly beyond cardiovascular medicine. Studying this process provides mechanistic insights into metabolic disease and identifies therapeutic targets, as exemplified by siRNA-based drugs targeting lipoprotein(a).
• Essential for systemic lipid transport and energy distribution.
• Determines plasma levels of LDL, VLDL, HDL, and lipoprotein(a).
• Dysregulation causes diabetic dyslipidaemia and hypertriglyceridaemia.
• Elevated lipoprotein(a) is an independent cardiovascular risk factor.
• APOE isoforms influence Alzheimer's disease risk through lipid metabolism.
• VLDL assembly is a target for therapeutic intervention in metabolic disorders.
• Intracellular tPA-PAI-1 interaction regulates VLDL assembly in hepatocytes.
• CRISPR screens can identify novel regulators of lipoprotein assembly.
What Happens During plasma lipoprotein particle assembly?
Apolipoprotein synthesis and lipid loading in the endoplasmic reticulum
In simple terms: The cell first makes the protein scaffold and starts adding fats to it inside the endoplasmic reticulum.
The assembly of VLDL begins in the endoplasmic reticulum (ER) with the synthesis of apolipoprotein B (APOB). APOB is co-translationally translocated into the ER lumen, where it is lipidated by microsomal triglyceride transfer protein (MTTP). This initial lipidation step is essential for the formation of a primordial lipoprotein particle. In the absence of MTTP, APOB is degraded, and VLDL assembly fails. The ER also serves as the site where chylomicrons are assembled in enterocytes, using a similar APOB-dependent mechanism.
Primordial particle formation and second-step lipidation
In simple terms: The partially built particle gets more fats added to it, becoming a mature lipoprotein.
After initial lipidation, the primordial APOB-containing particle undergoes a second step of lipidation, which involves the addition of a large lipid droplet to form a mature VLDL particle. This step requires the function of SAR1B and COPII vesicles, which facilitate the transport of the particle from the ER to the Golgi. Mutations in SAR1B cause chylomicron retention disease, highlighting the importance of this trafficking step. The second-step lipidation is a critical regulatory point in VLDL assembly.
Intracellular regulation by tPA-PAI-1 interaction
In simple terms: A protein interaction inside liver cells acts as a switch to control how much VLDL is assembled.
Recent studies have identified that the interaction between tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) within hepatocytes determines VLDL assembly. This intracellular interaction modulates the availability of lipids for APOB lipidation and influences the rate of VLDL secretion. The tPA-PAI-1 complex thus represents a novel regulatory node in lipoprotein assembly, linking fibrinolytic factors to lipid metabolism.
Lipoprotein(a) assembly and APOE-containing particle formation
In simple terms: Some lipoproteins, like Lp(a), are built by attaching additional proteins to an existing LDL-like particle.
Lipoprotein(a) [Lp(a)] is assembled by the covalent attachment of apolipoprotein(a) to an LDL-like particle containing APOB. This assembly occurs extracellularly and is a distinct process from VLDL assembly. APOE, another key apolipoprotein, is involved in the assembly and remodeling of HDL and VLDL remnants. APOE-containing particles are critical for lipid transport in the brain and periphery. The assembly of these particles is relevant to both cardiovascular and neurodegenerative diseases.
Key Genes Involved in GO:0034377 plasma lipoprotein particle assembly
The following genes encode proteins with well-documented roles in plasma lipoprotein particle assembly, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOB | Structural backbone of VLDL, IDL, LDL, and Lp(a) | Mutations cause familial hypobetalipoproteinemia; target for lipid-lowering therapies |
| APOA1 | Structural backbone of HDL | Key for reverse cholesterol transport; studied in atherosclerosis |
| APOE | Lipid transport in brain and periphery; binds to LDL receptors | Isoforms influence Alzheimer's disease risk |
| MTTP | Lipidates APOB in the ER; essential for VLDL assembly | Mutations cause abetalipoproteinemia |
| SAR1B | COPII component; required for ER-to-Golgi transport of VLDL | Mutations cause chylomicron retention disease |
| LPA | Encodes apolipoprotein(a); forms Lp(a) with APOB | Elevated Lp(a) is a cardiovascular risk factor |
| PLG | Plasminogen; related to tPA-PAI-1 system | May influence VLDL assembly via fibrinolytic pathway |
| SERPINE1 | Encodes PAI-1; interacts with tPA to regulate VLDL assembly | Modulates intracellular lipid handling |
| PLAT | Encodes tPA; interacts with PAI-1 in hepatocytes | Regulates VLDL assembly |
| CREB3L3 | Transcription factor regulating lipid metabolism | May control expression of lipoprotein assembly genes |
| TM6SF2 | Involved in VLDL secretion | Mutations associated with fatty liver disease |
| PNPLA3 | Lipid droplet remodeling; affects VLDL assembly | I148M variant linked to NAFLD |
| ANGPTL3 | Regulates plasma lipid levels | Target for lipid-lowering therapies |
| APOC3 | Inhibits lipoprotein lipase; modulates VLDL catabolism | Mutations cause hypertriglyceridaemia |
| LDLR | Receptor for LDL; clears APOB-containing particles | Mutations cause familial hypercholesterolaemia |
| ABCA1 | Lipidates APOA1 to form HDL | Mutations cause Tangier disease |
| SCARB1 | HDL receptor; involved in cholesterol uptake | Studied in reverse cholesterol transport |
| CETP | Transfers cholesteryl esters between lipoproteins | Target for HDL-raising therapies |
How Is plasma lipoprotein particle assembly Regulated?
Plasma lipoprotein particle assembly is regulated at multiple levels. Transcriptionally, factors such as CREB3L3 and other transcription factors control the expression of APOB and MTTP. Post-translationally, the interaction between tPA and PAI-1 within hepatocytes modulates VLDL assembly, linking fibrinolytic activity to lipid metabolism. Hormonal and nutritional status also influence assembly; insulin resistance in diabetic dyslipidaemia is associated with overproduction of VLDL. Additionally, the availability of lipids and the activity of COPII proteins such as SAR1B regulate the trafficking and secretion of assembled particles.
plasma lipoprotein particle assembly and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOB | Familial hypobetalipoproteinemia; cardiovascular disease | Knockout or point-mutation in hepatocytes |
| MTTP | Abetalipoproteinemia | Knockout in HepG2 or primary hepatocytes |
| SAR1B | Chylomicron retention disease | Knockout in intestinal epithelial cells |
| LPA | Elevated Lp(a); cardiovascular risk | Overexpression in hepatocytes; siRNA knockdown |
| APOE | Alzheimer's disease; cardiovascular disease | Knock-in of APOE4 in mice or iPSCs |
Diabetic dyslipidaemia and cardiovascular disease
Diabetic dyslipidaemia is characterized by elevated VLDL and triglyceride levels, often accompanied by low HDL and increased small dense LDL. These abnormalities arise in part from increased hepatic VLDL assembly and secretion, which is driven by insulin resistance and altered substrate availability. Elevated lipoprotein(a), another APOB-containing particle, is an independent risk factor for cardiovascular disease, and therapeutic approaches such as siRNA targeting LPA are being developed. Thus, dysregulation of GO:0034377 directly contributes to atherosclerotic risk.
Alzheimer's disease and neurodegeneration
Apolipoprotein E (APOE) is the major lipid transport protein in the brain and is involved in the assembly and remodeling of HDL-like particles in the central nervous system. The APOE4 isoform is the strongest genetic risk factor for late-onset Alzheimer's disease, influencing amyloid-beta deposition and clearance. While the assembly of brain lipoproteins differs from plasma lipoprotein assembly, the shared molecular machinery and apolipoprotein functions highlight the broader relevance of GO:0034377 to neurodegeneration.
Monogenic disorders of lipoprotein assembly
Mutations in genes essential for lipoprotein assembly cause rare monogenic diseases. Loss-of-function mutations in MTTP cause abetalipoproteinemia, characterized by the absence of APOB-containing lipoproteins. Mutations in SAR1B cause chylomicron retention disease, in which enterocytes fail to secrete chylomicrons. These disorders underscore the non-redundant roles of specific assembly factors and provide insights into the stepwise nature of the process.
From plasma lipoprotein particle assembly-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate VLDL assembly? | CRISPR knockout in HepG2 or primary hepatocytes |
| Does a specific point mutation in APOB affect lipidation? | Point mutation knock-in in hepatocyte cell lines |
| Can a tagged version of MTTP be used to track assembly? | Knock-in of fluorescent tag at endogenous locus |
| Does overexpression of SAR1B enhance lipoprotein secretion? | Overexpression in intestinal or hepatic cells |
| What is the role of tPA-PAI-1 interaction in VLDL assembly? | Knockout of PLAT or SERPINE1 in hepatocytes |
| Can CRISPR library screening identify novel assembly regulators? | Genome-wide knockout screen in lipoprotein-secreting cells |
How to Study the plasma lipoprotein particle assembly Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function phenotype | Identify essential assembly genes |
| Point mutation knock-in | Effect of specific variants | Model patient mutations in APOB or MTTP |
| Tagged knock-in | Protein localization and dynamics | Track APOB trafficking in live cells |
| Overexpression | Gain-of-function and rescue | Test sufficiency of assembly factors |
| Density gradient ultracentrifugation | Lipoprotein particle distribution | Isolate VLDL, LDL, HDL fractions |
| Western blotting | Apolipoprotein expression and processing | Assess APOB and APOA1 levels |
| Fluorescence microscopy | Intracellular localization | Visualize ER-to-Golgi transport |
| Lipid quantification | Triglyceride and cholesterol content | Measure assembly output |
CRISPR knockout and point mutation models
CRISPR-Cas9 knockout of candidate genes in hepatocyte-derived cell lines (e.g., HepG2, Huh7) allows assessment of their requirement for lipoprotein assembly. Point mutations can be introduced to model patient-specific variants, such as those in APOB or MTTP, and to dissect domain functions. These models are complemented by knockout in primary hepatocytes or intestinal organoids for more physiological relevance.
Knock-in and tagged knock-in approaches
Knock-in of epitope or fluorescent tags at endogenous loci enables real-time tracking of apolipoproteins and assembly factors. For example, tagging APOB with GFP allows visualization of particle formation and trafficking in live cells. Knock-in of disease-associated mutations, such as APOE4, provides isogenic models for mechanistic studies.
Overexpression and rescue experiments
Overexpression of wild-type or mutant cDNAs is used to test sufficiency and to rescue knockout phenotypes. This approach is particularly useful for studying auxiliary factors like SAR1B or tPA-PAI-1 components. Overexpression of LPA in hepatocytes can model elevated Lp(a) levels and test therapeutic siRNAs.
Biochemical and imaging assays
Lipoprotein assembly is measured by density gradient ultracentrifugation, gel filtration, and Western blotting for APOB and APOA1. Fluorescence microscopy and live-cell imaging track the intracellular trafficking of tagged apolipoproteins. Lipid quantification assays (e.g., triglyceride and cholesterol measurements) assess the functional output of assembly.
How CRISPR Can Be Used to Study GO:0034377 plasma lipoprotein particle assembly
Knockout
CRISPR knockout is used to ablate candidate genes and determine their necessity for plasma lipoprotein particle assembly. For example, knockout of MTTP or SAR1B in hepatocyte cell lines results in defective VLDL assembly and secretion, validating their essential roles. Knockout of PLAT or SERPINE1 can test the involvement of the tPA-PAI-1 system in VLDL assembly. Genome-wide knockout screens can identify novel regulators of lipoprotein assembly.
Point Mutation
Point mutation knock-in allows modeling of disease-associated missense variants in genes such as APOB, MTTP, or APOE. For instance, introducing the APOE4 allele into isogenic iPSCs or cell lines enables study of isoform-specific effects on lipoprotein assembly and function. Point mutations in APOB can dissect the domains required for MTTP-mediated lipidation.
Knock-in
Knock-in of reporter tags (e.g., GFP, HA) at endogenous loci facilitates tracking of apolipoproteins and assembly factors in real time. Knock-in of human APOB or LPA into mouse models can humanize lipoprotein metabolism for drug testing. Conditional knock-in using Cre-lox systems allows tissue-specific expression of mutant alleles.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression is used to increase expression of genes involved in lipoprotein assembly, testing sufficiency and gain-of-function effects. Overexpression of SAR1B or MTTP can enhance VLDL secretion in cell models. Overexpression of LPA in hepatocytes models elevated Lp(a) and enables testing of siRNA therapeutics.
How EDITGENE Supports plasma lipoprotein particle assembly Research
Researchers studying plasma lipoprotein particle assembly-related genes often need to determine whether a candidate gene is causally involved in the process, which requires precise genetic models. EDITGENE provides a comprehensive suite of CRISPR-based services to support such investigations, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for plasma lipoprotein particle assembly research.
Frequently Asked Questions About plasma lipoprotein particle assembly
What is GO:0034377 plasma lipoprotein particle assembly?
GO:0034377 is a Gene Ontology biological process term defined as the non-covalent aggregation and arrangement of proteins and lipids to form plasma lipoprotein particles.
What genes are involved in plasma lipoprotein particle assembly?
Key genes include APOB, APOA1, APOE, MTTP, SAR1B, LPA, PLAT, and SERPINE1, among others.
Why is lipoprotein assembly important for health?
It enables lipid transport in blood; dysregulation causes cardiovascular disease, diabetic dyslipidaemia, and other metabolic disorders.
How is VLDL assembly regulated?
VLDL assembly is regulated by MTTP-mediated lipidation, SAR1B-dependent trafficking, and intracellular tPA-PAI-1 interaction.
What diseases are linked to defects in lipoprotein assembly?
Abetalipoproteinemia, chylomicron retention disease, familial hypercholesterolaemia, and elevated Lp(a) are linked to defects in this process.
What is the role of APOB in lipoprotein assembly?
APOB is the structural backbone of VLDL, IDL, LDL, and Lp(a), and its lipidation by MTTP is essential for particle formation.
How can CRISPR be used to study lipoprotein assembly?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes involved in lipoprotein assembly.
What is lipoprotein(a) and how is it assembled?
Lp(a) is formed by covalent attachment of apolipoprotein(a) to an LDL-like particle containing APOB, and elevated levels increase cardiovascular risk.
Which cell models are used to study lipoprotein assembly?
HepG2, Huh7, primary hepatocytes, and intestinal organoids are commonly used, along with CRISPR-engineered derivatives.
What methods measure lipoprotein assembly?
Density gradient ultracentrifugation, Western blotting for APOB, fluorescence microscopy, and lipid quantification are standard methods.
Conclusion
GO:0034377 plasma lipoprotein particle assembly is a fundamental biological process that governs lipid transport and metabolic homeostasis. Its dysregulation is implicated in prevalent diseases ranging from cardiovascular disorders to neurodegeneration, making it a high-priority area for mechanistic and therapeutic research. The application of CRISPR-based genetic models, combined with biochemical and imaging assays, provides a robust framework for dissecting the genes and pathways controlling lipoprotein assembly. Continued investigation of this process promises to yield new targets for treating dyslipidaemias and related conditions.
References
- 1. Nissen SE et al.. 2023. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.. JAMA 330(21):2075-2083 PMID: 37952254
- 2. van Zwol W et al.. 2024. VLDL Biogenesis and Secretion: It Takes a Village.. Circ Res 134(2):226-244 PMID: 38236950
- 3. Huang Y et al.. 2014. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.. Neurobiol Dis 72 Pt A:3-12 PMID: 25173806
- 4. Adiels M et al.. 2006. Diabetic dyslipidaemia.. Curr Opin Lipidol 17(3):238-46 PMID: 16680028
- 5. Dai W et al.. 2023. Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes.. Science 381(6661):eadh5207 PMID: 37651538
- 6. Biolo M et al.. 2026. Focus on lipoprotein(a).. Eur Heart J Suppl 28(Suppl 5):v181-v186 PMID: 42099476
- 7. Devaraj S et al.. 2026. Biochemistry, Apolipoprotein B.. PMID: 30844166
